Drug therapy has dominated glaucoma management for decades, but novel device technologies are shifting the way this disease is managed, adding promising new options to the previously limited treatment continuum. For companies active in this field, along with an increasing number of VCs targeting ophthalmology, this shift marks the beginning of a tremendous new opportunity--one that will involve challenges and risks, but that also offers a huge payoff for those able to provide the right technology at the right time.
by Mary Thompson
Drug therapy has dominated glaucoma management for decades, but novel device technologies are now helping to spur a paradigm shift in the way this disease is managed, adding promising new...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
